Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

94.75 -0.37 (-0.38%)
Streaming Delayed Price Updated: 2:21 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
ANI Pharmaceuticals's Earnings Outlook
 
Via Benzinga
Truist Securities Maintains Buy Rating for ANI Pharmaceuticals: Here's What You Need To Know
 
Via Benzinga
Why Is Generic Drug Player ANI Pharmaceuticals Stock Trading Lower Today?
ANI Pharmaceuticals Inc's (NASDAQ: ANIP) third-quarter revenues were $131.8 million, up 57.3% Y/Y, beating the  
Via Benzinga
Expert Ratings for ANI Pharmaceuticals
 
Via Benzinga
Analyst Expectations for ANI Pharmaceuticals's Future
 
Via Benzinga
ANI Pharmaceuticals Inc. (NASDAQ: ANIP) Records 52-Week High Wednesday Morning
Via Investor Brand Network
What 4 Analyst Ratings Have To Say About ANI Pharmaceuticals
 
Via Benzinga
Where ANI Pharmaceuticals Stands With Analysts
 
Via Benzinga
Looking Into ANI Pharmaceuticals's Return On Capital Employed
 
Via Benzinga
Why ANI Pharmaceuticals Stock Is Soaring Today
ANI Pharmaceuticals Inc's (NASDAQ: ANIP) Q1 revenues were $106.8 million, +65.6% Y/Y, beating the  
Via Benzinga
7 A-Rated Biotech Stocks for Your August Buy List
Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge. 
Via InvestorPlace
ANI Pharmaceuticals to Present at the Jefferies Healthcare Conference
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Announces FDA Approval and Commercialization of Two ANDAs with CGT Exclusivity
From ANI Pharmaceuticals, Inc.
Via Business Wire
Earnings Preview For ANI Pharmaceuticals
 
Via Benzinga
ANI Pharmaceuticals Earnings Perspective: Return On Capital Employed
 
Via Benzinga
ANI Pharmaceuticals Announces Pricing of $75 Million Public Offering of Common Stock
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Announces Proposed Public Offering of Common Stock
From ANI Pharmaceuticals, Inc.
Via Business Wire
Stocks Reverse Gains Ahead Of Slew Of Inflation Data
Stocks are lower this afternoon, as investors await a deluge of inflation data amid a rally for the banking sector. 
Via Talk Markets
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Tredegar Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Trevena, Inc. (NASDAQ: TRVN) shares surged 170% to $1.74 after the company announced the approval of OLINVYK in China. 
Via Benzinga
ANI Pharmaceuticals Reports Record First Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals to Discuss First Quarter 2023 Financial Results on May 8, 2023, at 8:30 a.m. ET
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Announces the FDA Approval and Launch of Nitrofurantoin Oral Suspension USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Announces the FDA Approval of Colestipol Hydrochloride Tablets USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Reports Record Fourth Quarter Financial Results and Achieves Full Year 2022 Revenue Milestone; Initiates 2023 Guidance
From ANI Pharmaceuticals, Inc.
Via Business Wire
Guggenheim Creates Bullish Pitch For ANI Pharma On Progress With Cortrophin Launch
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
 
Via Benzinga
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023, at 8:30 a.m. ET
From ANI Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.